PATIENT_ID,LINE_NUMBER,LINE_NAME,START_DATE,END_DATE,LINE_TYPE,IS_MAINTENANCE,ADD_EXEMPTION,SUB_EXEMPTION,GAP_EXEMPTION,NAME_EXEMPTION,LAST_ACTIVITY_DATE,LAST_ENROLLMENT_DATE,LINE_END_REASON,ENHANCED_COHORT,INDEX_DATE
66,1,"Carboplatin,Pembrolizumab,Pemetrexed",8/10/17,9/6/18,combo,FALSE,FALSE,FALSE,FALSE,FALSE,6/16/19,6/16/19,Passed discontinuation gap,NSCLC,8/10/17
66,2,Crizotinib,2/9/19,2/9/19,mono,FALSE,FALSE,FALSE,FALSE,FALSE,6/16/19,6/16/19,Last row hit,NSCLC,8/10/17
97,1,"Bevacizumab,Carboplatin,Pemetrexed",8/10/16,8/31/16,combo,FALSE,FALSE,FALSE,FALSE,FALSE,5/20/18,5/20/18,New line started with new drugs,NSCLC,8/10/16
97,2,"Bevacizumab,Carboplatin,Paclitaxel",10/17/16,5/15/17,combo,FALSE,FALSE,FALSE,FALSE,FALSE,5/20/18,5/20/18,New line started with new drugs,NSCLC,8/10/16
97,3,Nivolumab,8/1/17,10/12/17,mono,FALSE,FALSE,FALSE,FALSE,FALSE,5/20/18,5/20/18,Last row hit,NSCLC,8/10/16
12,1,"Cisplatin,Pemetrexed",1/28/18,8/27/18,combo,FALSE,FALSE,FALSE,FALSE,FALSE,7/1/19,7/1/19,Entering continuation maintenance therapy,NSCLC,1/28/18
12,2,Carboplatin,7/22/18,8/27/18,mono,TRUE,FALSE,FALSE,FALSE,FALSE,7/1/19,7/1/19,New line started with new drugs,NSCLC,1/28/18
12,3,Durvalumab,10/13/18,7/1/19,mono,FALSE,FALSE,FALSE,FALSE,FALSE,7/1/19,7/1/19,Last row hit,NSCLC,1/28/18